Explain When Study Results Are Clinically Meaningful to Patients
November 2017
It can be hard to decide whether STATISTICALLY significant findings are CLINICALLY significant.
Consider the new COMPASS trial in patients with stable CV disease. It's stirring up controversy...and is a good example.
It suggests that adding Xarelto (rivaroxaban) 2.5 mg BID to low-dose aspirin reduces the risk of a CV event versus aspirin alone...with a p-value less than 0.001.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote